• Galmed completed the acquisition of Colospan, making the medical device developer a wholly owned subsidiary.
• Reworked consideration replaced a planned USD 2 million share issuance with an extra USD 800,000 cash payment.
• The remaining value shifted to a capped USD 2 million earnout starting in Q3 2027, based on CG-100 net sales tiers of 7% and 9%.
• Earnout can accelerate on a strategic transaction involving the acquired business or IP, or if Galmed raises at least USD 17.5 million in equity financings.
• Deal adds CG-100, a CE-marked colorectal surgery device in the EU/Israel, positioning Galmed for earlier revenue generation from 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galmed Pharmaceuticals Ltd. published the original content used to generate this news brief on June 22, 2026, and is solely responsible for the information contained therein.